Stocks · News reference
Scinai Immunotherapeutics shares are trading higher after the company announced a development and manufacturing agreement with a biopharma company, boosting committed customer orders to $7.6 million, up 300% from year-end 2025.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Scinai Immunotherapeutics shares are trading lower after the company announced a $4 million private placement and warrant inducement transaction.
Scinai Immunotherapeutics Announces ~$4M Financing Via $1.20/ADS Private Placement And Warrant Inducement Repricing April 2026 Warrants To $1.20/ADS
Why Is Scinai Immunotherapeutics Stock Gaining Tuesday?
Scinai Immunotherapeutics stock jumped 27% after securing a $5.1M biopharma manufacturing deal. Details on SCNI's major contract win.